Adjuvant vemurafenib in resected, BRAF V600...

The Lancet Oncology 2018 / 2

Adjuvant vemurafenib in resected, BRAF V600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial

Maio, Michele, Lewis, Karl, Demidov, Lev, Mandalà, Mario, Bondarenko, Igor, Ascierto, Paolo A, Herbert, Christopher, Mackiewicz, Andrzej, Rutkowski, Piotr, Guminski, Alexander, Goodman, Grant R, Simmo
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Language:
english
Journal:
The Lancet Oncology
DOI:
10.1016/S1470-2045(18)30106-2
Date:
February, 2018
File:
PDF, 338 KB
english, 2018
Conversion to is in progress
Conversion to is failed